Another GST polymorphism that was analyzed in CRC patients receiving FOLFOX6 treatment can be seen in the study of Stoehlamacher et al., who found that the GSTP1 IleVal genotype is associated with increased survival in patients receiving this treatment [44]. Here, GSTP1 is linked to colorectal carcinoma.